跳转至内容
Merck
CN
  • Microfluidic capture of endothelial colony-forming cells from human adult peripheral blood: phenotypic and functional validation in vivo.

Microfluidic capture of endothelial colony-forming cells from human adult peripheral blood: phenotypic and functional validation in vivo.

Tissue engineering. Part C, Methods (2014-08-06)
Ruei-Zeng Lin, Adam Hatch, Victor G Antontsev, Shashi K Murthy, Juan M Melero-Martin
摘要

Endothelial colony-forming cells (ECFCs) are endothelial progenitors that circulate in peripheral blood and are currently the subject of intensive investigation due to their therapeutic potential. However, in adults, ECFCs comprise a very small subset among circulating cells, which makes their isolation a challenge. Currently, the standard method for ECFC isolation relies on the separation of mononuclear cells and erythrocyte lysis, steps that are time consuming and known to increase cell loss. Alternatively, we previously developed a novel disposable microfluidic platform containing antibody-functionalized degradable hydrogel coatings that is ideally suited for capturing low-abundance circulating cells from unprocessed blood. In this study, we reasoned that this microfluidic approach could effectively isolate rare ECFCs by virtue of their CD34 expression. We conducted preclinical experiments with peripheral blood from four adult volunteers and demonstrated that the actual microfluidic capture of circulating CD34(+) cells from unprocessed blood was compatible with the subsequent differentiation of these cells into ECFCs. Moreover, the ECFC yield obtained with the microfluidic system was comparable to that of the standard method. Importantly, we unequivocally validated the phenotypical and functional properties of the captured ECFCs, including the ability to form microvascular networks following transplantation into immunodeficient mice. We showed that the simplicity and versatility of our microfluidic system could be very instrumental for ECFC isolation while preserving their therapeutic potential. We anticipate our results will facilitate additional development of clinically suitable microfluidic devices by the vascular therapeutic and diagnostic industry.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
1,2-二氯乙烷, ACS reagent, ≥99.0%
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
N-羟基丁二酰亚胺, 98%
Sigma-Aldrich
N-羟基硫代琥珀酰亚胺 钠盐, ≥98% (HPLC)
Sigma-Aldrich
氯化铵, ReagentPlus®, ≥99.5%
Sigma-Aldrich
1,2-二氯乙烷, anhydrous, 99.8%
Sigma-Aldrich
乙二胺四乙酸, ACS reagent, 99.4-100.6%, powder
Sigma-Aldrich
单克隆抗-肌动蛋白,α-平滑肌, clone 1A4, ascites fluid
Sigma-Aldrich
氯化铵, Molecular Biology, suitable for cell culture, ≥99.5%
Sigma-Aldrich
乙二胺四乙酸, anhydrous, crystalline, BioReagent, suitable for cell culture
Sigma-Aldrich
乙二胺四乙酸 溶液, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
乙二胺四乙酸 二钠盐 溶液, BioUltra, pH 8.0, ~0.5 M in H2O
Sigma-Aldrich
荧光素 5(6)-异硫氰酸酯, BioReagent, suitable for fluorescence, mixture of 2 components, ≥90% (HPLC)
Sigma-Aldrich
荧光素异硫氰酸酯异构体I, suitable for protein labeling, ≥90% (HPLC), powder
Sigma-Aldrich
乙二胺四乙酸, 99.995% trace metals basis
Sigma-Aldrich
乙二胺四乙酸, BioUltra, anhydrous, ≥99% (titration)
Sigma-Aldrich
氯化铵, 99.998% trace metals basis
Sigma-Aldrich
八甲基三硅氧烷, 98%
Sigma-Aldrich
聚二甲基硅氧烷, viscosity 1.0 cSt (25 °C)
Sigma-Aldrich
乙二胺四乙酸, purified grade, ≥98.5%, powder
Supelco
氯化铵, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
氯化铵, 99.99% trace metals basis
Sigma-Aldrich
荧光素 5(6)-异硫氰酸酯, ≥90% (HPLC)
Sigma-Aldrich
荧光素异硫氰酸酯异构体I, ≥97.5% (HPLC)
Sigma-Aldrich
氯化铵, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, 99.5-100.5% (calc. to the dried substance)
Sigma-Aldrich
乙二胺四乙酸, ≥98.0% (KT)
Sigma-Aldrich
氯化铵, BioUltra, ≥99.5% (AT)
Supelco
1,2-二氯乙烷, analytical standard
Sigma-Aldrich
N-羟基丁二酰亚胺, purum, ≥97.0% (T)
Sigma-Aldrich
乙二胺四乙酸, BioUltra, ≥99.0% (KT)